[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preeclampsia-pe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preeclampsia-pe":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,66,95,123,162,184,220,242,265,289,316,345,370,394,415,444,472,502,525],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":49,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100586442","personalized-care-for-prenatal-stress-reduction--prevention-of-preterm-birth-ptb-disparities-100586442",false,"NCT06915428","Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities","Personalized Toolkit Building a Comprehensive Approach to Resource Optimization and Empowerment in Pregnancy & Beyond (PTBCARE+) A Randomized Controlled Trial (RCT) of Personalized Care for Prenatal Stress Reduction and Preterm Birth Disparities Prevention","PTBCARE+","Inclusion Criteria:\n\n1. Viable, singleton pregnancy, 8+0 to 19+6 weeks, dated by last menstrual period ± ultrasound using standard obstetric criteria per American College of Obstetricians and Gynecologists.\n\n   Gestational age at first ultrasound by last menstrual period (LMP) \u002F Ultrasound method \u002F Measurement agreement with LMP required • Up to 8 weeks 6 days \u002F crown rump length \u002F ± 5 days\n   * 9 weeks 0 days to 13 weeks 6 days \u002F crown rump length \u002F ± 7 days\n   * 14 weeks 0 days to 15 weeks 6 days \u002F standard fetal biometry \u002F ± 7 days\n   * 16 weeks 0 days to 19 weeks 6 days \u002F standard fetal biometry \u002F ± 10 days\n   * Gestational dating \u002F fetal viability must be confirmed by ultrasound prior to enrollment \u002F randomization.\n   * Ultrasound report must include documentation of normal fetal heart rate of ≥ 120 beats per minute, or subsequent medical record documentation of auscultation of fetal heart rate ≥ 120 beats per minute.\n   * Viability must be confirmed \u002F re-confirmed within 7 days of randomization.\n\n   If initial consent occurs early in pregnancy and V1\u002Frandomization occur later, viability must be reconfirmed to ensure ongoing eligibility prior to initiating V1 activities (including surveys) and proceeding with randomization.\n2. No signs or symptoms of, or clinical diagnosis of, evolving miscarriage, active preterm labor, preterm prelabor rupture of membranes at the time of enrollment.\n\n   * Cervical dilation at the time of enrollment is an exclusion criterion. However, cervical evaluation and digital cervical exam is not required prior to enrollment.\n\n     (3a) High a priori risk for medically indicated preterm birth - must meet at least one of the following 3 criteria (maternal medical history, prior pregnancy history, or moderate risk factor history)\n   * miPTB criteria #1: Maternal Medical History - any one of the following:\n\n     o Known chronic hypertension requiring medications in the 3 months prior to conception or prior to 22 weeks gestation.\n\n     o At least 2 blood pressure readings 6 hours apart, \\\u003C20 weeks gestation, with systolic ≥ 130 mmHg or diastolic ≥ 80 mmHg \\*regardless of need for medication or formal diagnosis of hypertension in chart\\*\n\n     o Pre-gestational diabetes mellitus.\n     * Diabetes diagnosed \\\u003C20 weeks gestation.\n     * Maternal chronic or sub-acute renal disease, including chronic kidney failure, chronic renal insufficiency, glomerulonephritis, lupus nephritis, defined as any:\n\n       \\*biopsy proven chronic renal disease history; and\u002For\n\n       \\*serum creatinine ≥ 1.1 mg\u002FdL at any time during pregnancy prior to enrollment, in the absence of other identifiable transient factors per clinician's assessment (e.g., extreme dehydration, cystitis, pyelonephritis); and\u002For\n\n       \\*chronic proteinuria, defined as baseline urine protein:creatinine ratio ≥ 0.30 mg\u002FdL or 24 hour total urine protein ≥ 300 mg in the absence of other identifiable transient factors per clinician's assessment (e.g., extreme dehydration, cystitis, pyelonephritis)\n\n       \\*Systemic Lupus Erythematosus\n       * Antiphospholipid Antibody Syndrome\n   * miPTB criteria #2: Prior pregnancy history - any ONE of the following: o Previous pregnancy complicated by preeclampsia or hypertensive disorders of pregnancy at any gestational age, in a singleton gestation; the fetus must not have had major structural anomalies or aneuploidy.\n\n     o Previous history of stillbirth ≥ 16+0 weeks in a singleton gestation; the fetus must not have had major structural anomalies or aneuploidy. The stillbirth etiology must not have been attributed to physical trauma (e.g., domestic violence, motor vehicle accident) or illicit drug use (e.g., cocaine use leading to abruption and stillbirth).\n   * miPTB criteria #3: Any two or more of the following moderate risk factors: o Nulliparity, defined as no prior pregnancy to reach at least 20 weeks gestation note that this is the traditional \u002F classic definition of 'nulliparous' and that there is overlap between nulliparity as defined this way and 'preterm birth' due to cervical insufficiency, which allows for deliveries in the 16-19 week gestational age range to be considered as 'preterm births'\n\n     o Obesity: current or pre-pregnancy body mass index ≥30 kg\u002Fm\\^2\n\n     o Family history: first degree relative with a history of preeclampsia\n\n     o Advanced maternal age: maternal age ≥ 35 years at estimated date of confinement\n\n     o Prior adverse obstetric history - one or more of the following:\n\n     \\- history of low birth weight or small for gestational age baby in a singleton gestation, defined as weight \\\u003C10% for gestational age and fetal sex; the fetus must not have had major structural anomalies or aneuploidy.\n\n     \\- history of adverse pregnancy outcome in a singleton gestation; the fetus must not have had major structural anomalies or aneuploidy.\n\n     o Long interpregnancy interval: ≥ 10 year (3650 day) pregnancy interval, defined as the time (in days) between the date of delivery of the last pregnancy to reach ≥ 20 weeks gestation and the first day of the last menstrual period for the current pregnancy.\n\n     o Black or African-American race (as a proxy for underlying racism) - self-reported. Participants who self-identify as being of more than one racial group will be considered to be of Black race for the purposes of this criterion if one of the racial groups is Black or African-American.\n     * Low socioeconomic status, defined as one or more of the following: housing or food insecurity noted in chart within the last year, self-pay or Medicaid insurance, less than high school education\n\nand\u002For\n\n(3b) High a priori risk for spontaneous preterm birth - must meet at least one of the following 2 criteria (prior pregnancy history or current pregnancy course)\n\n* sPTB criteria #1: Prior pregnancy history\n\n  * EITHER a history of a delivery of a singleton, non-anomalous baby between 16+0 and 34+6 weeks gestation or delivery of a twin, non-anomalous pregnancy between 160 \u002F7and 276 \u002F7 weeks gestation due to spontaneous preterm labor, preterm premature rupture of membranes, cervical insufficiency, or placental abruption - Chart documentation of prior preterm birth, the gestational age of the prior preterm birth (referred to as the 'qualifying delivery') should be determined. If the gestational age at delivery is obtained directly from the medical record and more than one gestational age appears, the greater of the two will be used assuming that neither is the 'source document' (i.e. an ultrasound report with a due date, a c-section report, a delivery note, etc).\n\nUse the following table as a validation of the previous delivery. For example, if the infant was male and weighed more than 2763 grams (6 pounds, 1.5 ounces) then the patient would be ineligible based on history of a preterm birth criteria. This table should only be used to determine whether the qualifying delivery is most likely to be preterm less than 35 weeks gestation when the gestational age CANNOT be verified\u002Fcalculated by review of the medical records or is not available in the medical records.\n\nGestational age 90th percentile - boys 90th percentile - girls 33 weeks \\> 2488g 5 lbs 7.8 oz \\> 2116g 4 lbs 10.6 oz 34 weeks \\> 2763g 6 lbs 1.5 oz \\> 2379g 5 lbs 3.9 oz 35 weeks \\> 3084g 6 lbs 12.8 oz \\> 2661g 5 lbs 13.9 oz\n\n* Documented history of a prior pregnancy complicated by asymptomatic cervical shortening \\\u003C25mm between 16+0 and 23+6 weeks gestation or cervical dilation ≥ 0.5cm requiring cervical cerclage placement prior to 24+0 weeks gestation, even if delivery ultimately occurred ≥ 35 weeks gestation or at term.\n\n  • sPTB criteria #2: Current pregnancy course\n* Asymptomatic cervical shortening \\\u003C25mm in the current pregnancy, diagnosed by transvaginal ultrasound that is performed ≥14+0 weeks gestation, per Registered Diagnostic Medical Sonographer(RDMS) certified Sonographer or physician with transvaginal ultrasound training program (or similar) qualifications\n* Cervical cerclage in situ in the current pregnancy due to concern for risk of preterm birth, at the discretion of the primary obstetric provider\n\n  (4) Ability to provide written, informed consent in English or Spanish\n\n  (5) Planned prenatal care at the University of North Carolina at Chapel Hill obstetrics clinics and planned delivery at the University of North Carolina Women's Hospital (Chapel Hill, NC).\n\nExclusion Criteria:\n\n1. Participation in another intervention based clinical trial during pregnancy that is deemed, at the discretion of the investigative team for the current study or the other concurrent study, to conflict with this research and\u002For confound the study results.\n\n   o There are some concurrent studies, even those designed to test an intervention, which may be compatible with the current study; this will be reviewed by the investigative leadership team on a case-by-case basis.\n2. Previous participation in the PTBCARE+ program in another pregnancy, with randomization to the PTBCARE+ (active intervention) group.\n3. Current, ongoing, illicit drug use ≥ 12 weeks gestation.\n\n   * Use of tobacco and\u002For marijuana products is not an exclusion.\n   * Receiving treatment for opioid use disorder with methadone, suboxone, or similar in an approved treatment program is not an exclusion.\n4. History of radical trachelectomy\n5. Planned voluntary termination of pregnancy.\n6. Heavy vaginal bleeding or large subchorionic hemorrhage - defined as:\n\n   * Bleeding as primary reason for unplanned clinic evaluation or emergency room visit within 14 days of potential enrollment\n   * Subjective bleeding accompanied by ≥ 4 point drop in the hematocrit within 14 days of potential enrollment\n   * Subchorionic hemorrhage or abruption on formal ultrasound with a volume ≥ 64 cubic cm (4cm x 4cm x 4cm) within 14 days of potential enrollment\n7. Major congenital anomaly such as major structural deficit of the heart, lungs, brain, or other major organ system\n\n   1. Mild renal abnormalities, clubfoot, isolated cleft lip\u002Fpalate, etc. in the fetus are not a reason for exclusion.\n   2. Isolated 'soft markers' for aneuploidy (such as choroid plexus cysts, echogenic bowel, etc.) are not a reason for exclusion.\n   3. If a major congenital anomaly is diagnosed \\*after\\* enrollment, the patient will continue to participate in the study, however, the investigators will plan to analyze the study results with and without these individuals included.\n8. Positive aneuploidy screening test (traditional biochemical assay, e.g., quad screen - risk of aneuploidy of 1:25 or higher or cell free deoxynucleic acid (DNA) test result that is screen positive for trisomy 13, trisomy 18, trisomy 21, or sex chromosome abnormality) in the absence of definitive fetal karyotype evaluation.\n\n   * Definitive fetal karyotype evaluation can only be obtained through direct testing of the tissue from the conceptus - by chorionic villus sampling or amniocentesis during pregnancy.\n   * The term \"suspected aneuploidy\" is commonly used in the medical record but this is not a diagnosis and by itself is not informative and not an exclusion criteria.\n9. Cystic hygroma or abnormally thickened nuchal translucency ≥ 3 mm at any time in the current gestation, regardless of subsequent diagnostic testing results.\n\n   * Note that a cystic hygroma remains an exclusion criterion regardless of subsequent diagnostic testing results because fetuses with this history carry an elevated risk of major congenital heart disease.\n   * Fetal echocardiogram is most accurately performed at 22-24 weeks gestation, which is later than the enrollment gestational age window.\n10. Polyhydramnios at or prior to enrollment.\n\n    o Polyhydramnios is defined as a maximum vertical pocket ≥ 8.0 cm, given that polyhydramnios \\\u003C22 weeks has a high likelihood of being associated with congenital anomalies\u002Faneuploidy and\u002For preterm birth due to preterm prelabor rupture of membranes.\n11. For potential participants who meet eligibility criteria ONLY due to prior spontaneous or medically indicated preterm birth: if the prior preterm birth was in a pregnancy complicated by twins, confirmed fetal aneuploidy, or major congenital fetal anomalies in the absence of another pregnancy meeting inclusion criteria they are not eligible.\n12. Known HIV positive with viral load greater than 1,000 copies\u002FmL or cluster of differentiation 4 (CD4) count less than 350\u002Fmm\\^3\n13. Unwillingness to undergo randomization.","FEMALE","18 Years",{"count":20,"type":21},1228,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a personalized prenatal support program \\[(Personalized Toolkit Building a Comprehensive Approach to Resource optimization and Empowerment in Pregnancy \\& Beyond, (PTBCARE+)\\] works to lower stress and lower the risk of early delivery in pregnant individuals at high-risk for delivering preterm. The main question\\[s\\] it aims to answer are:\n\n* Does the PTBCARE+ patient support program lower patient-reported stress levels during pregnancy?\n* Does the PTBCARE+ patient support program improve biologic measures of stress during pregnancy?\n* Does the PTBCARE+ patient support program result in a higher chance of delivering a healthy baby at or close to full term?\n\nResearchers will compare people who participate in the PTBCARE+ patient support program to those receive usual care to see if the PTBCARE+ patient support program lowers patient-reported stress, improves biologic measures of stress, and increases the chance of delivering a healthy baby at or close to full term.\n\nParticipants will be randomly assigned to receive the PTBCARE+ patient support program or usual prenatal care.\n\nAll participants will be asked to:\n\n* complete 2 study visits during pregnancy - including completing electronic surveys, providing a blood and urine sample, measuring the heart rate variability by a clip or the ear or finger, and body composition evaluation using a simple scale-like device.\n* complete one study visit postpartum that includes completing electronic surveys, and measuring heart rate variability. Blood and urine sample collection and body composition evaluation via InBody scale are optional at the postpartum visit.\n\nPeople who are randomly assigned to receive the PTBCARE+ support program will receive several resources to help them during pregnancy. These things include items such as:\n\n* a stress reduction toolkit;\n* access to an online website that can also be downloaded as a smart phone app;\n* the option to receive an electronic massage while in clinic, and more.\n* additional support gifts provided at routine clinical appointments\n\nPeople who are randomly assigned to receive usual prenatal care will not receive any additional support resources from the study during pregnancy.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48],"Preterm Birth Complication","Preterm Birth","Preterm Birth Recurrence","Preeclampsia","Preeclampsia (PE)","Hypertensive Disorders of Pregnancy","Support Program","Stress","Resilience, Psychological","Empowerment, Patient","Emotional Stress","Pregnancy","Pregnancy Complications","Pregnancy Induced Hypertension","Neonates and Preterm Infants","Cervical Insufficiency","Social Determinants of Health (SDOH)","Cervical Shortening","Disparities in Pregnancy Complications","Disparities","Prenatal Care","Care Coordination",[15,50,51,52],"pregnancy-related disparities","patient support program","enhanced prenatal care","NOT_YET_RECRUITING","2026-06-25",{"date":56,"type":57},"2026-06-29","ACTUAL",{"date":59,"type":21},"2026-08-01",{"date":61,"type":21},"2029-01",{"name":63,"class":64},"University of North Carolina, Chapel Hill","OTHER",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":76,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100565558","non-invasive-preeclampsia-screening-and-biobank-100565558","NCT06643741","Non-Invasive Preeclampsia Screening and Biobank","Collection of Pregnancy Outcome Data and Whole Blood Samples From Women Undergoing Non-Invasive Screening for Early, Preterm, and Term Preeclampsia","Inclusion Criteria:\n\n* Subject is female and 18 years of age and older;\n* Subject provides a signed and dated informed consent;\n* Subject is pregnant with a singleton pregnancy at ≥11.0 - ≤14.0 weeks' gestation;\n* Subject agrees to provide the Sponsor access to any prenatal and postnatal screening or diagnostic test results and supporting data;\n* Subject agrees to have UtAPI calculated during their SOC first trimester ultrasound and MAP collected at the first trimester SOC visit;\n* Subject agrees to provide up to 25mL of whole blood at each trimester visit;\n* Subject agrees to provide relevant medical and pregnancy\u002Fpostnatal information including outcome.\n\nExclusion Criteria:\n\n* Subject is unlikely to return for second and third trimester testing;\n* Subject is unlikely to have pregnancy outcome data available;\n* Previous sample donation under this protocol with the same pregnancy;\n* Subject is participating in a blinded aspirin study or taking unknown doses of aspirin.",true,{"count":75,"type":21},6550,"6 Months","OBSERVATIONAL","Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.",[31],[81,82],"preeclampsia","pregnant","RECRUITING","2026-06-09",{"date":86,"type":57},"2026-06-11",{"date":88,"type":57},"2025-02-02",{"date":90,"type":21},"2026-07-01",{"name":92,"class":93},"Sequenom, Inc.","INDUSTRY",21,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100571130","validation-of-the-maira-preeclampsia-test-for-screening-earlylate-preeclampsia-in-first-and-second-trimesters-100571130","NCT06716242","Validation of the MaiRa Preeclampsia Test for Screening Early\u002FLate Preeclampsia in First and Second Trimesters","Prospective, Observational, Multicentre Study to Confirm the Performance of Molecular Screening for Early Detection of Preeclampsia","iPregnostic","Inclusion Criteria:\n\n* Signed informed consent approved by the Ethics Committee.\n* Women ≥18 years of age at consent.\n* Single gestation pregnancies with first sample collection (T1) possible between 9 and 14 weeks' gestation.\n\nExclusion Criteria:\n\n* Active neoplasm.\n* History of organ or bone marrow transplantation.\n* Maternal transfusion within 8 weeks before sample collection.\n* Evidence of early pregnancy loss at consent.\n* Severe, uncontrolled infections.\n* Other investigator-assessed risks that could compromise participation or data quality.",{"count":104,"type":21},7473,"Preeclampsia (PE) is a major obstetric complication with severe short- and long-term consequences for both mother and fetus. Early detection is critical to mitigate PE-related morbidity and mortality. Effective screening tools are needed to identify women at risk, enabling timely preventive and therapeutic interventions.\n\nCurrent screening methods primarily target placental biomarkers like sFLT1 and PlGF, which are limited to short-term predictions near symptom onset. Existing first-trimester assessments that incorporate maternal factors and Doppler metrics remain constrained by low sensitivity (\\\u003C41%) in compliance with NICE and ACOG guidelines.\n\nRecent advancements in cell free RNA (cf-RNA) analysis have revealed potential in first-trimester PE prediction. Findings from the PREMOM study (NCT04990141) established a molecular profile for early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE) through cfRNA analysis, culminating in the development of the MaiRa Preeclampsia Test (Maternal Advanced and Innovative Preeclampsia Risk Assessment), which demonstrated high predictive performance for first- and second-trimester screening.\n\nThe current study hypothesizes that the MaiRa Preeclampsia Test is generalizable, maintaining its predictive accuracy in an independent cohort.",[31],[108,109,110,111,112],"Early Screening","First Trimester Diagnostic","Cell-Free RNA (cfRNA)","Molecular Profile","Blood Biomarkers","2026-05-13",{"date":115,"type":57},"2026-05-15",{"date":117,"type":57},"2024-12-02",{"date":119,"type":21},"2027-02",{"name":121,"class":93},"iPremom",11,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":134,"studyType":77,"phases":4,"briefSummary":135,"conditions":136,"keywords":145,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":65},"100636441","cardiometabolic-disease-and-substrate-metabolism-100636441","NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","45 Years",{"count":133,"type":21},50,"9 Months","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[30,137,31,138,139,140,141,142,143,38,39,144],"Gestational Diabetes Mellitus (GDM)","Preeclampsia (PE) Risk","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Cardiometabolic Diseases","Insulin Resistance","Placental Dysfunction","Gestational Complications",[146,147,30,139,148,149,150,151,152],"Cardiometabolic disease","Substrate metabolism","Insulin resistance","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","2026-04-27",{"date":155,"type":57},"2026-05-04",{"date":157,"type":57},"2025-12-10",{"date":159,"type":21},"2027-08",{"name":161,"class":64},"University of Tennessee Graduate School of Medicine",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":65},"100284932","phase-2-progesterone-to-enhance-the-efficacy-and-success-of-expectantly-managed-preterm-severesuperimposed-preeclampsia-100284932","NCT02989025","Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe\u002FSuperimposed Preeclampsia","Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe\u002FSuperimposed Preeclampsia-The PROGRESS Pilot Study","PROGRESS","Inclusion Criteria:\n\n* UMMC antepartum patients with preterm PE between 23 0\u002F7ths and 34 0\u002F7ths weeks gestation when initially evaluated\n* Willing and able to understand study procedures and to provide informed consent\n\nExclusion Criteria:\n\n* \\>33 weeks gestational age or \\\u003C23 weeks gestation\n* Maternal compromise requiring emergent delivery (ongoing placental abruption, DIC, pulmonary edema).\n* Fetal compromise requiring emergent delivery (fetal bradycardia, recurrent late fetal heart rate decelerations, minimal to absent fetal heart rate variability).\n* Parameters according to current practice guidelines that exclude a patient from expectant management include the following:\n* Preterm premature rupture of membranes (PPROM) \\> 34 weeks gestation;\n* Platelet count \\\u003C 100,000\u002Fmicroliter (thrombocytopenia) with evidence of HELLP syndrome;\n* Persistently abnormal hepatic enzyme concentrations (twice or more upper normal values);\n* Severe fetal growth restriction (ultrasound-estimated fetal weight less than fifth percentile);\n* Severe Oligohydramnios (AFI \\\u003C 5cm)\n* Reversal of end diastolic flow(REDF) in umbilical artery Doppler testing;\n* Recurrent (\\> 2 readings \\> 30 minutes apart) severe hypertension despite antihypertensive therapy;\n* Eclampsia;\n* Pulmonary edema;\n* Abruption placentae;\n* Nonreassuring fetal status during daily testing (biophysical profile \\\u003C4\u002F10 and\u002For recurrent variable or late decelerations);\n* IUFD",{"count":171,"type":21},60,[173],"PHASE2","The purpose of this study is to learn if giving 17-hydroxyprogesterone caproate (17 OHPC) to mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby outcomes.",[38,31],{"date":177,"type":57},"2026-05-01",{"date":179,"type":57},"2017-05-22",{"date":181,"type":21},"2027-01-31",{"name":183,"class":64},"University of Mississippi Medical Center",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":192,"conditions":193,"keywords":200,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":219},"100594112","the-combined-first-trimester-screening-100594112","NCT07015203","The Combined First Trimester Screening","Inclusion Criteria:\n\n* A woman over 18 years old in the first trimester of pregnancy (11th-13th gestational week)\n* Signed the Consent to Participate in the Project and GDPR.\n\nExclusion Criteria:\n\n* Unsigned the Consent to Participate in the Project and the Consent to the Processing of Personal Data.",{"count":191,"type":21},2000,"The project is a national, prospective, multicenter pilot project. The project is focus on setting up the combined first trimester screening in the Czech Republic.\n\nThe combined first trimester screening is aimed at predicting and detecting the most serious obstetric complications, such as the great obstetrical syndromes (preeclampsia, fetal growth restriction, preterm labor and intrauterine fetal demise \"IUFD\") and structural congenital defects (morphological and chromosomal).\n\nThe primary objective of the project is to create a unified methodology for performing and evaluating the combined first trimester screening in connection with the National Health Information System (hereinafter referred to as \"NHIS\"), which will enable recording, providing analysis and linking recorded clinical parameters with data in the NHIS. The pilot project will also provide data for modeling appropriate mechanisms for reimbursement from public health insurance.",[31,194,195,196,197,198,199],"Fetal Growth Restriction","Congenital Abnormalities","Preterm Labor","Intrauterine Fetal Demise","Genetics Syndrome","Pregnancy Overdue - Week 41+6",[81,201,202,203,204,205,206,207,208],"prediction","prevention","maternal risk factors","Mean Arterial Pressure","Uterine artery Pulsatility Index","Placental Growth Factor","acetylsalicylic acid","Czech Republic","2026-04-16",{"date":211,"type":57},"2026-04-17",{"date":213,"type":57},"2025-06-15",{"date":215,"type":21},"2027-04-30",{"name":217,"class":218},"Institute of Health Information and Statistics of the Czech Republic","OTHER_GOV",3,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":228,"targetDuration":230,"studyType":77,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":65},"100632428","preeclampsia-origin-characteristics-and-effects-on-mother-and-baby-100632428","NCT07513558","Preeclampsia: Origin, Characteristics and Effects on Mother and Baby","Face to Face With Preeclampsia: Understanding Its Origin, Characteristics and Effects on Mother and Baby","GRAZ-PE","Inclusion Criteria:\n\n* Ongoing pregnancy with preeclampsia regardless the gestational age diagnosed for PE\n\nExclusion Criteria:\n\n* Maternal or fetal genetic abnormalities",{"count":229,"type":21},250,"12 Weeks","Preeclampsia (PE) is a serious pregnancy complication characterized by new-onset hypertension and signs of maternal organ dysfunction, often accompanied by placental abnormalities and systemic endothelial dysfunction. PE is associated with adverse maternal and perinatal outcomes and confers an increased long-term risk of cardiovascular and metabolic disease for both mother and offspring.\n\nThis prospective observational cohort study aims to establish a longitudinal pregnancy and birth cohort of women diagnosed with preeclampsia. Pregnant women with a clinical diagnosis of PE according to current obstetric guidelines will be recruited at their initial presentation either in the in- or outpatient clinic or in the delivery ward, respectively and followed through late pregnancy, delivery, and early postpartum.\n\nParticipants will undergo study visits during pregnancy, sample collection at delivery, and a postpartum visit 8-12 weeks after birth. Clinical data, physical measurements, questionnaire-based information, and biological samples will be collected from mothers and infants to enable comprehensive phenotyping of pregnancies complicated by preeclampsia.\n\nData and biosamples from this cohort will be used for descriptive and hypothesis-driven analyses and may be compared with data from an existing longitudinal cohort of healthy pregnancies to support interpretation of preeclampsia-associated biological and clinical changes.",[31,38],"2026-04-09",{"date":235,"type":57},"2026-04-13",{"date":237,"type":57},"2026-03-01",{"date":239,"type":21},"2036-03",{"name":241,"class":64},"Medical University of Graz",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":253,"conditions":254,"keywords":255,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":262,"locationsCount":264},"100479345","impact-of-first-trimester-preeclampsia-screening-on-perinatal-and-maternal-morbidity-ranspre-100479345","NCT05521776","Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE)","Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity : a Multicenter Randomized Trial","RANSPRE","Inclusion Criteria :\n\n* Pregnancy between 11 and 14 WG\n* Age ≥18 years\n* Affiliated to or beneficiary of a health insurance system (including AME)\n* Signed informed consent\n\nExclusion Criteria :\n\n* Gestational age \\\u003C11 WG or \\>14 WG\n* Known ectopic pregnancy\n* Known non-ongoing pregnancy\n* Known multiple pregnancy\n* History of PE in a previous pregnancy\n* Pregnancies complicated by major fetal abnormality identified at the first-trimester ultrasound if performed before randomization\n* Absence of health insurance\n* Contra-indication to aspirin (bleeding disorders such as von Willebrand's disease, active peptic ulceration, hypersensitivity to aspirin, active peptic ulceration, NSAID-exacerbated respiratory disease, severe liver or heart dysfunction)\n* Women taking low-dose aspirin regularly and started before pregnancy (except ART indication)\n* Age \\\u003C18 years\n* Poor understanding of the French language",{"count":251,"type":21},14500,[24],"The purpose of this study is to determine whether first-trimester screening for preeclampsia based on the FMF algorithm (a combination of maternal clinical, sonographic and biochemical parameters), improves maternal or perinatal health.",[31],[30],"2026-03-24",{"date":258,"type":57},"2026-03-27",{"date":260,"type":57},"2023-03-06",{"date":119,"type":21},{"name":263,"class":64},"Assistance Publique - Hôpitaux de Paris",22,{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":73,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":273,"targetDuration":76,"studyType":77,"phases":4,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":219},"100630243","prevention-of-preeclampsia-in-denmark-a-national-implementation-study-100630243","NCT07485140","Prevention of Preeclampsia in Denmark: A National Implementation Study","Prevention of Preeclampsia in Denmark (PREPRED): A National Implementation Study","PREPRED","Inclusion Criteria:\n\n* Pregnant women with a viable singleton pregnancy\n* Attendance at a routine first-trimester ultrasound scan at 11+0 to 13+6 weeks of gestation at a Danish maternity hospital during the study period\n* Valid Danish personal identification number (CPR number) enabling linkage with national health registries\n\nExclusion Criteria:\n\n* Multiple pregnancy (e.g., twins or higher-order gestations)\n* Major fetal anomaly diagnosed before completion of first-trimester screening\n* Miscarriage or pregnancy loss diagnosed before completion of first-trimester screening",{"count":274,"type":21},80000,"The goal of this clinical study is to learn if a new first-trimester screening program can better find pregnant women who are at high risk of developing preeclampsia and help prevent the condition with early treatment.\n\nPreeclampsia is a pregnancy condition that causes high blood pressure and can affect the mother's organs and the baby's growth. Early detection allows doctors to offer preventive treatment, such as low-dose aspirin, which may lower the risk of serious illness.\n\nThe study includes pregnant women with a single pregnancy who attend their routine first-trimester scan at maternity hospitals in Denmark.\n\nThe main questions it aims to answer are:\n\nDoes the new screening program lower the number of women who develop preterm preeclampsia (preeclampsia before thirty-seven weeks of pregnancy)?\n\nCan the screening program be carried out safely and be acceptable for pregnant women and healthcare professionals?\n\nResearchers will gradually introduce the new screening program across hospitals and compare outcomes before and after the program starts. Women who are found to have a high risk of preeclampsia will be offered preventive treatment with low-dose aspirin.\n\nParticipants will:\n\nReceive information about preeclampsia and the screening during their first-trimester visit\n\nHave their blood pressure measured and an ultrasound assessment of blood flow to the uterus during the routine scan\n\nHave routine blood samples analysed to estimate their personal risk of preeclampsia\n\nBe offered daily low-dose aspirin until late pregnancy if they are identified as high risk\n\nContinue standard pregnancy care while researchers follow pregnancy outcomes using national health records\n\nThe study will help researchers understand whether this screening approach works in everyday care and whether it should become part of routine pregnancy care in Denmark.",[31],[278,279,30],"Prevention","Screening","2026-03-16",{"date":282,"type":57},"2026-03-20",{"date":284,"type":57},"2025-09-15",{"date":286,"type":21},"2027-11",{"name":288,"class":64},"Copenhagen University Hospital at Herlev",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":73,"sex":17,"minAge":297,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":65},"100628612","a-study-to-find-and-confirm-blood-based-markers-called-proteins-that-may-show-early-heart-changes-in-women-with-preeclampsia-even-before-symptoms-appear-and-the-use-of-heart-ultrasound-echocardiography-to-look-at-patterns-of-how-the-heart-changes-during-pregnancy-in-women-with-preeclampsia-100628612","NCT07463898","A Study to Find and Confirm Blood-based Markers (Called Proteins) That May Show Early Heart Changes in Women With Preeclampsia, Even Before Symptoms Appear, and the Use of Heart Ultrasound (Echocardiography) to Look at Patterns of How the Heart Changes During Pregnancy in Women With Preeclampsia.","PRoteomics and EchoCardiography for Identifying Subclinical Cardiac Dysfunction in Preeclampsia (PRECISE)","PRECISE","Inclusion Criteria:\n\n* • Pregnant women who are up to 20 weeks pregnant\n\n  * Able to consent to participate in the study\n  * Are enrolled in the ENHANCE-CVH study\n  * Willing to undergo echocardiography and blood draws\n\nExclusion Criteria:\n\n* • Known cardiac disease (e.g., cardiomyopathy, coronary artery disease \\[CAD\\])\n\n  * Sickle cell disease\n  * Pulmonary arterial hypertension\n  * Pulmonary embolism\n  * Inability to provide informed consent\n  * Acute Illness\n  * Malignancy","13 Years","50 Years",{"count":300,"type":21},172,"The goal of this study is to find and confirm blood-based markers (called proteins) that may show early heart changes in women with preeclampsia, even before symptoms appear. It will also use heart ultrasound (echocardiography) to look at patterns of how the heart changes during pregnancy in women with preeclampsia. The main questions it aims to answer are:\n\n* Do these blood markers relate to heart changes on ultrasound?\n* How may they help predict future health problems for the mother?\n\nParticipants will:\n\n* Complete a 20-minute survey that will include taking your baseline demographic information, clinical information\u002Fmedical history, asking about pre-existing health conditions, including measuring your height, weight, and blood pressure.\n* Have transthoracic echocardiography (TTE) performed at 12 - 16 weeks gestation and again at 28 - 32 weeks gestation.\n* Provide a blood sample for these protein measurements. These samples will be collected at intake (12 - 16 weeks gestation) and again at 28 - 32 weeks gestation.",[303,138,31],"Cardiovascular Biomarkers",[305,81,306],"cardiac phenotypes","cardiovascular biomarkers","2026-03-05",{"date":309,"type":57},"2026-03-11",{"date":311,"type":21},"2026-03",{"date":313,"type":21},"2027-12",{"name":315,"class":64},"Washington University School of Medicine",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":326,"briefSummary":327,"conditions":328,"keywords":331,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":344},"100600552","phase-2-statin-intervention-for-severe-early-onset-placental-insufficiency-statin-pre-trial-100600552","NCT07098975","Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial)","Statin Intervention for Severe Early-Onset Placental Insufficiency: A Randomized Controlled Trial Assessing Daily Administration as a Treatment Strategy (STATIN-PRE Trial)","STATIN-PRE","Inclusion Criteria:\n\n* Singleton fetus.\n* Between 24+0 to 29+6 weeks of gestation at the inclusion.\n* Early-onset severe PE: women with a diagnosis of severe-preterm PE who are candidates for expectant management and have no clinical indication for immediate delivery, based on the clinical assessments of the attending doctors.\n\nAnd\u002For\n\n* IUGR: Diagnosis of early onset IUGR according to the SMFM classification with umbilical artery Doppler with absent\u002Freversed diastolic flow; or estimated fetal weight \\\u003C10th percentile plus pulsatility index (PI) of umbilical artery Doppler \\>95th percentil.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Established maternal or fetal compromise that necessitated immediate delivery\n* Abnormal karyotype, structural abnormalities, or congenital infections.\n* Treatment with pravastatin or other statins prior to inclusion.\n* Lactose intolerance",{"count":325,"type":21},154,[173],"In pregnancies with placental insufficiency, the only available treatment is close monitoring to determine the point at which the risks of preterm birth for the baby are lower than the risks of continuing the pregnancy. Therefore, safely prolonging pregnancy is the current management goal for this condition.\n\nStatins, such as pravastatin, are approved and marketed drugs used to prevent cardiovascular disease. Recent studies suggest that statins may help treat pregnancy complications and prolong pregnancy, thereby avoiding extreme prematurity and improving long-term health outcomes for both mother and baby.\n\nPrevious clinical trials have shown the ability of statins to stabilize angiogenic factors, thus reducing obstetric complications associated with placental insufficiency. In 2015, a study reported that pravastatin was effective in stabilizing blood pressure and reducing proteinuria associated with preeclampsia. More recently, in 2020, it was demonstrated that in pregnant women with fetal growth restriction treated with pravastatin, the sFlt-1\u002FPlGF ratio was lower than in untreated women, indicating a slower progression of placental insufficiency.\n\nThis study proposes administering a daily dose of 40 mg of pravastatin between 24 and 29.6 weeks of gestation to mothers diagnosed with preeclampsia and\u002For fetal growth restriction. One group of women will receive the medication, while another group will receive a visually identical but inactive pill (a placebo), allowing us to determine whether any observed improvement in pregnancy is attributable to the medication. Assignment to the treatment or placebo group will be random, and neither the mothers nor the healthcare professionals caring for them will know which group they are in.\n\nThe investigators also aim to examine whether this intervention during pregnancy protects the cardiovascular system. For this reason, the investigators will assess both the mother and the baby six months after birth using an ultrasound of the heart and blood vessels, and the investigators will also perform a blood test on the mothers. Additionally, the investigators want to explore the needs and expectations of women who experience these complications during pregnancy and postpartum, so that their stories can guide us in finding answers and solutions that are as personalized as possible to the real needs of families. After the visit at six months postpartum, yhe investigators will follow up with annual phone calls over the next four years to check on the participants' health and their baby's. During each call, the investigators will review the participant's health status and talk about how the participant is feeling. All of this will help us ensure that the treatment does not cause any long-term issues and will improve future care for other mothers and babies.\n\nA total of 154 pregnant women are expected to be included in order to meet the study's objectives.",[31,329,330],"Intrauterine Growth Restriction (IUGR)","Placental Insufficiency",[30,332,330,333,334],"Intrauterine growth restriction","statins","Pravastatin","2026-02-19",{"date":337,"type":57},"2026-02-23",{"date":339,"type":57},"2026-01-14",{"date":341,"type":21},"2028-07",{"name":343,"class":64},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",2,{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":352,"targetDuration":354,"studyType":77,"phases":4,"briefSummary":355,"conditions":356,"keywords":359,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":65},"100620376","cardiovascular-risk-assessment-in-young-women-after-index-pregnancy-with-and-without-placental-complications-100620376","NCT07356817","Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications","CARDIOMOM","Inclusion Criteria:\n\n* Patients who participated in the BiSC (Barcelona Life Study Cohort), EuroPE (Randomized open-label control trial to evaluate if the incorporation of sFlt1\u002FPlGF ratio in the diagnosis and classification of PE improves maternal and perinatal outcomes in women with suspicion of the disease; PI16\u002F00375) and AngioCor (Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: clinical and experimental approach, PI19\u002F00702) cohort studies\n* Who have delivered within the previous 3-6 years.\n* Give written consent when invited to participate in this study protocol.\n\nExclusion Criteria:\n\n* Unwillingness to participate in this study\n* Probability of loss to follow-up.",{"count":353,"type":21},1260,"1 Day","In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women often prioritize their families over themselves, making it more difficult to maintain a healthy lifestyle that could reduce their cardiovascular risk. Furthermore, the investigators will evaluate how environmental exposures influence their health, as well as explore potential strategies for prediction and prevention.\n\nThe goal is to develop an easy-to-use algorithm or test that allows women and their physicians to assess this risk, ideally in the form of a mobile app. Although predictive algorithms for cardiovascular health already exist, most have been developed using predominantly male or older populations, and none have taken into account pregnancy-related events or environmental exposure - both of which are key determinants of women's cardiovascular health.",[357,31,358],"Cardiovascular (CV) Risk","Fetal Weight",[81,360,361],"Cardiovascular Risk","app","2026-01-12",{"date":364,"type":57},"2026-01-21",{"date":366,"type":57},"2023-08-28",{"date":368,"type":21},"2026-12-31",{"name":343,"class":64},{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":4},"100615989","evaluation-of-patients-with-hypertensive-disorders-of-pregnancy-an-ambispective-observational-study-100615989","NCT07299773","Evaluation of Patients With Hypertensive Disorders of Pregnancy: An Ambispective Observational Study","PREP","Inclusion Criteria:\n\n* Pregnancies complicated by preeclampsia or gestational hypertension ≥22 weeks\n* Age ≥18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* intrauterine fetal demise\n* Major fetal anomalies or chromosomal abnormalities\n* Maternal cardiac disease or ongoing cardiologic therapy\n* Chronic kidney disease\n* Twin or multiple pregnancies\n* Pregestational diabetes",{"count":378,"type":21},120,"The overall objective of this study is to evaluate the prognostic role of ultrasound and laboratory parameters, specifically their potential ability to predict severe forms of preeclampsia and adverse maternal-fetal outcomes.\n\nIn particular, the aim of the present research is to obtain data on the prognostic value of ultrasonographic and biochemical parameters in patients with hypertensive disorders of pregnancy.",[30,31,381],"Hypertensive Disorder of Pregnancy",[81,383,384],"ophtalmic nerve","ophtalmic artery","2025-12-17",{"date":387,"type":57},"2025-12-23",{"date":389,"type":21},"2026-01-01",{"date":391,"type":21},"2027-12-01",{"name":393,"class":64},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":400,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":65},"100596125","comparing-the-efficacy-of-75mg-versus-150mg-aspirin-for-the-prevention-of-preeclampsia-in-high-risk-pregnant-women-100596125","NCT07041385","Comparing the Efficacy of 75mg Versus 150mg Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women","Inclusion Criteria:\n\n1. Screen positive women\n2. Age 18 - 30 y\n3. Gestational Age 11 - 13+6 weeks\n4. Singleton Pregnancy\n5. Estimated risk for preterm PE of \\> 1 in 100 (Reference - Fetal Medicine Foundation)\n\nExclusion Criteria:\n\n1. Screen negative women\n2. Age \\> 30 y\n3. Gestational Age \\> 14 weeks\n4. Multiple Gestation\n5. Estimated risk for preterm PE of \\\u003C 1 in 100 (Reference - Fetal Medicine Foundation)","30 Years",{"count":402,"type":21},340,[24],"This study aims to evaluate the effectiveness of 75 mg aspirin versus 150 mg aspirin in preventing preeclampsia among individuals with high risk for the condition. Existing literature suggests that the 150 mg aspirin dose may exhibit superior efficacy, yet inconclusive evidence exists in our local setting.",[31],"2025-10-02",{"date":408,"type":57},"2025-10-08",{"date":410,"type":21},"2025-11-01",{"date":412,"type":21},"2027-06-30",{"name":414,"class":64},"Shalamar Hospital",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":422,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":65},"100577789","relationship-between-aspirin-metabolism-and-markers-of-metabolic-dysfunction-among-pregnant-persons-at-risk-of-pre-eclampsia-100577789","NCT06802861","Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia","RAMP","Inclusion Criteria:\n\n* Recommended aspirin for pre-eclampsia prevention by OB\u002FGYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors)\n\n  * Willingness to adhere to aspirin therapy\n  * Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n  * Gestational age at enrollment \\\u003C16 weeks\n  * Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n\n  * Type 1 Diabetes Mellitus\n  * Current gestational diabetes mellitus\n  * Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n  * Thrombophilia\n  * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n  * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n  * Current or recent use of steroids\n  * Current use of prophylactic or therapeutic anticoagulation\n  * Medical contraindication to aspirin therapy\n  * Molar pregnancy\n  * Renal disease\n  * Inability or unwillingness to give informed consent\n  * Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators",{"count":133,"type":21},"This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.",[30,31,138,425,38,39,139,140,144],"Obesity and Obesity-related Medical Conditions",[427,428,429,430,431,432,433,434,435],"metabolic dysfunction","gestational diabetes","pregnancy","maternal obesity","maternal insulin resistance","aspirin metabolism","GDM","substrate oxidation","gestational glucose intolerance","2025-09-03",{"date":438,"type":57},"2025-09-10",{"date":440,"type":57},"2025-01-01",{"date":442,"type":21},"2028-12-31",{"name":161,"class":64},{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":451,"targetDuration":76,"studyType":77,"phases":4,"briefSummary":453,"conditions":454,"keywords":459,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":468,"leadSponsor":470,"locationsCount":65},"100594124","renal-functions-in-preeclamptic-pregnant-women-using-neutrophil-gelatinase-associated-lipocalin-ngal-and-standard-renal-function-tests-100594124","NCT07015359","Renal Functions in Preeclamptic Pregnant Women Using Neutrophil Gelatinase-associated Lipocalin (NGAL) and Standard Renal Function Tests","Evaluation of the Effect of Spinal Anesthesia-Induced Hypotension on Renal Functions in Preeclamptic Pregnant Women Using Neutrophil Gelatinase-associated Lipocalin (NGAL) and Standard Renal Function Tests","Inclusion Criteria:\n\n* Patients classified as ASA physical status II-III\n* Pregnant women aged 18-45 years, diagnosed with preeclampsia and scheduled for elective cesarean section, will be included in the study.\n\nExclusion Criteria:\n\n* Patients who are unable to read, understand, or sign the informed consent form\n* Patients with a diagnosed renal disease\n* Patients who do not wish to participate in the study\n* Patients with ASA physical status greater than III\n* Patients younger than 18 or older than 45 years\n* Patients requiring sedation or undergoing general anesthesia\n* Patients with cardiac instability\n* Patients with known arrhythmias",{"count":452,"type":21},46,"Acute kidney injury (AKI) is a significant postoperative complication. Risk factors for AKI include impaired renal perfusion, decreased functional renal reserve, as well as advanced age, peripheral arterial disease, diabetes mellitus, renovascular disease and congestive heart failure. Mean arterial pressure (MAP) below 55-60 mmHg has been associated with postoperative AKI. Traditional diagnostic criteria for AKI include increased serum creatinine levels and oliguria. However, creatinine levels do not rise until more than half of renal function is lost. Serum and urine NGAL levels rise earlier-within 24-48 hours-making it a promising early biomarker.\n\nIn our study, hypotension is defined as systolic blood pressure \\\u003C100 mmHg or a \\>30% decrease in MAP. Patients requiring ephedrine under these conditions will be evaluated as the hypotension group and compared with non-hypotensive patients in terms of NGAL, BUN (blood urea nitrogen), creatinine, and GFR (Glomerular Filtration Rate) values at baseline and at the 4th postoperative hour.",[455,456,457,458,31],"Anesthesia","Spinal Aneshtesia","Acute Kidney Failure","Spinal Anesthesia Induced Hypotension",[30,460,461,462,463],"Hypotension","NGAL","Creatinine","AKI","2025-06-08",{"date":466,"type":57},"2025-06-11",{"date":464,"type":21},{"date":469,"type":21},"2025-10-20",{"name":471,"class":64},"Nihan Aydin Guzey",{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":498,"leadSponsor":500,"locationsCount":65},"100586834","postpartum-co-rehabilitation-100586834","NCT06920537","Postpartum CO Rehabilitation","Postpartum Cardio-obstetric Rehabilitation After Hypertensive Pregnancy","Inclusion Criteria:\n\n* are 3 to 6 months postpartum, willing, and able to give informed consent for participation;\n* are more than 18 years old;\n* are able to access and use a computer, mobile phone and internet (for online sessions);\n* were diagnosed with GH (BP higher than 139\u002F89 mmHg after 20 gestational weeks) or PE (BP higher than 139\u002F89 mmHg and proteinuria after 20 gestational weeks) during pregnancy.\n\nExclusion Criteria:\n\n* have chronic (pre-existing) hypertension (BP\\>139\u002F89 mmHg pre-pregnancy, \\\u003C20 weeks' gestation or after 6 weeks postpartum);\n* received antihypertensive drug therapy prior to pregnancy or after 6 weeks postpartum;\n* are taking beta-blockers for any reason;\n* participated in exercise activity programs regularly before 3-month postpartum (more than 2 hour of moderate-to-vigorous exercise per week);\n* have any musculoskeletal injury that can limit or contraindicate the practice of exercise;\n* have any major contraindications to exercise such as cardiomyopathy, cardiac arrhythmias and conduction abnormalities or congenital heart disease.",{"count":480,"type":21},40,[24],"Some women who develop high blood pressure during pregnancy, such as gestational hypertension or preeclampsia, may continue to have slightly or moderately high blood pressure after giving birth. This can increase their risk of heart disease later in life. Managing blood pressure and adopting a healthy lifestyle after pregnancy could help lower this risk.\n\nRight now, the investigators don't know much about how postpartum rehabilitation programs focused on heart and pregnancy-related health could help women with these conditions. However, a feasibility study suggests that exercise programs might help reduce blood pressure and encourage healthier lifestyles in these women.\n\nIn this study, the investigators are testing an 8-week exercise program to see how it affects blood pressure, fitness, and blood vessel health. The investigators will compare the results with a group of women who receive usual healthcare, which includes verbal advice on healthy living but no supervised exercise sessions.\n\nThis type of program, called cardio-obstetric rehabilitation, combines exercises for heart health with specialized care for women's health.",[484,31],"Gestational Hypertension",[486,487,488,489,490,491,492,493],"postpartum rehabilitation","physical exercise","blood pressure","Pelvic Floor","gestational hypertension","pre-eclampsia","small vessels","endothelial function","2025-05-12",{"date":496,"type":57},"2025-05-14",{"date":213,"type":21},{"date":499,"type":21},"2026-12-30",{"name":501,"class":64},"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal",{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":512,"conditions":513,"keywords":514,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":521,"leadSponsor":523,"locationsCount":65},"100586215","endothelial-dysfunction-for-prognosis-in-patients-with-preeclampsia-100586215","NCT06912477","Endothelial Dysfunction for Prognosis In Patients With preeClampSia","Systematic Evaluation of Endothelial Dysfunction as a Prognostic Marker for Outcomes in Women With Preeclampsia","EPICS","Inclusion Criteria:\n\n* singleton pregnancies\n* Age ≥ 18 years\n* Patient's ability to provide consent\n* written informed consent\n\nExclusion Criteria:\n\n* Lack of consent\n* Language barrier\n* Dark to very dark skin type\n* Severe fetal chromosomal\u002Fgenetic\u002Fstructural anomalies\n* Laboratory changes in LDH, creatinine, or platelets due to other causes (e.g., isolated thrombocytopenia, e.g., immune thrombocytopenia, carcinoma)",{"count":511,"type":21},385,"Preeclampsia is a pregnancy-specific hypertensive disorder and can progress rapidly to severe adverse outcomes affecting both the mother and the fetus. Endothelial and microcirculatory dysfunction mediate systemic preeclampsia-related organ dysfunctions. Changes in endothelial and vascular function in preeclampsia have been demonstrated through reduced flow-mediated vasodilation as a result of reduced availability of nitric oxide, which potentially persists up to several years postpartum. Hyperspectral imaging is a new innovative technology that allows to assess the peripheral microcirculation and perfusion non-invasively and contactless, but has never been evaluated in the context of preeclampsia before.\n\nThis EPICS project (Endothelial dysfunction for Prognosis In patients with preeClampSia) is a prospective observational study and aims to investigate hyperspectral imaging as a new potential diagnostic and prognostic marker in preeclampsia.",[31,381],[81,515,516],"hyperspectral imaging","endothelial dysfunction","2025-05-08",{"date":519,"type":57},"2025-05-11",{"date":517,"type":57},{"date":522,"type":21},"2027-07",{"name":524,"class":64},"Heidelberg University",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":534,"conditions":535,"keywords":536,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":547,"locationsCount":65},"100576928","different-regimens-of-magnesium-sulphate-in-patients-with-severe-preeclampsia-100576928","NCT06791668","Different Regimens of Magnesium Sulphate in Patients With Severe Preeclampsia","Comparison of Different Regimens of Magnesium Sulphate in Patients With Severe Preeclampsia in Ain Shams University Maternity Hospital (Retrospective Cohort)","Inclusion Criteria:\n\n* All hospital records of patients diagnosed as preeclampsia with severe features planned to receive magnesium sulphate.\n\nExclusion Criteria:\n\n* Records with missing data about the regimen of magnesium sulphate used",{"count":533,"type":21},400,"The goal of this observational study is to learn about the effects of the different drug regimens of magnesium sulphate in treatment of (severe pre-eclampsia). This condition affects some pregnant women and raises their blood pressure. It may also cause seizures (fits). The medication (magnesium sulphate) helps to prevent seizures. The main question this study aims to answer is:\n\nWhat are the different regimens of magnesium sulphate that are used to prevent seizures in pregnant women with severe pre-eclampsia?\n\nParticipants already have taken the magnesium sulphate as part of their regular medical care for severe pre-eclampsia. Researchers will look into the records of the participants in the past 5 years to collect the data.",[31],[537,538,539,540],"eclampsia","magnesium sulphate","intensive care unit","pulmonary edema","2025-01-19",{"date":543,"type":57},"2025-01-24",{"date":545,"type":57},"2024-12-03",{"date":311,"type":21},{"name":548,"class":64},"Ain Shams Maternity Hospital"]